◆英語タイトル:Cerus Corp (CERS) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8013829
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月22日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for use with three blood components, platelets, plasma and red blood cells. Cerus is marketed and sold in several countries worldwide including the US, Belgium, Kuwait, France, Spain, Portugal, Switzerland, CIS countries and other countries. Cerus is headquartered in Concord, California, the US.
Cerus Corp (CERS) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cerus Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Cerus Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Cerus Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Cerus Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Cerus Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Cerus Corp, Medical Equipment, Deal Details 11
Partnerships 11
Cerus Enters into Agreement with Kedrion Biopharma 11
Cerus Enters into Agreement with Haemonetics 12
Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan 13
Cerus Enters into Co-Marketing Agreement with Biomedica Foscama 14
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 15
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 16
Cerus Enters Into Distribution Agreement With Ilex Biotech 17
Equity Offering 18
Cerus Plans to Raise USD70 Million in Public Offering of Shares 18
Cerus Prices Public Offering of Shares for USD70 Million 19
Cerus Completes Public Offering Of Shares For US$40.3 Million 20
Cerus Corp – Key Competitors 22
Cerus Corp – Key Employees 23
Cerus Corp – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 02, 2017: Cerus Corporation Reports Third Quarter 2017 Results 25
Aug 03, 2017: Cerus Reports Second Quarter 2017 Results 27
May 03, 2017: Cerus Reports First Quarter 2017 Results 29
Mar 07, 2017: Cerus Reports Fourth Quarter and Year End 2016 Results 30
Nov 03, 2016: Cerus Reports Third Quarter 2016 Results 32
Aug 04, 2016: Cerus Reports Second Quarter 2016 Results 34
May 03, 2016: Cerus Corporation Reports First Quarter 2016 Results 36
Mar 08, 2016: Cerus Reports Fourth Quarter and Year End 2015 Results 38
Corporate Communications 40
Aug 09, 2016: Vivek Jayaraman Appointed as Cerus Corporation’s Chief Commercial Officer 40
Jan 11, 2016: Cerus Appoints New Leadership for Europe, Middle East and Africa Region 41
Product News 42
03/16/2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma 42
03/15/2016: Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA’s Revised Guidance Document on Bacterial Safety Standards for Platelets 43
03/09/2016: Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology 44
02/09/2016: Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma 45
01/14/2016: AABB Authorizes Use of the INTERCEPT Blood System for Platelets to Reduce the Risk of Transfusion-Associated Graft Versus Host Disease 46
01/05/2016: Cerus Announces Agreement with Blood Systems for the Use of INTERCEPT Platelets and Plasma 47
Product Approvals 48
Mar 16, 2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma 48
Other Significant Developments 49
Oct 31, 2017: Cerus and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEPT Blood System Portfolio in Italy 49
Jun 07, 2017: Cerus Provides Update on U.S. Platelet Additive Solution Supply 50
Oct 10, 2016: Cerus Announces that Hemolife Fundación Banco Nacional de Sangre Has Entered into Routine Use of the INTERCEPT Blood System 51
Jul 11, 2016: Cerus Provides an Update on Adoption by Blood Centers of America Members for the INTERCEPT Blood System for Platelets and Plasma 52
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
List of Tables
Cerus Corp, Medical Equipment, Key Facts, 2016 2
Cerus Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Cerus Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Cerus Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Cerus Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Cerus Corp, Deals By Market, 2011 to YTD 2017 9
Cerus Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Cerus Enters into Agreement with Kedrion Biopharma 11
Cerus Enters into Agreement with Haemonetics 12
Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan 13
Cerus Enters into Co-Marketing Agreement with Biomedica Foscama 14
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 15
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 16
Cerus Enters Into Distribution Agreement With Ilex Biotech 17
Cerus Plans to Raise USD70 Million in Public Offering of Shares 18
Cerus Prices Public Offering of Shares for USD70 Million 19
Cerus Completes Public Offering Of Shares For US$40.3 Million 20
Cerus Corp, Key Competitors 22
Cerus Corp, Key Employees 23
Cerus Corp, Subsidiaries 24